

# Equity Raising Presentation

May 2026

*Turning regulatory and clinical momentum into commercial scale*



**Imricor's vision is to bring iCMR to every cardiac centre in the world**

ersonal use only

# Disclaimer

This presentation has been prepared by Imricor Medical Systems, Inc. (**IMR** or **Imricor**) in connection with IMR's proposed capital raising (the **Capital Raise**), comprising a placement of CHES Depository Interests (**CDIs**) to certain sophisticated and professional investors;

By accepting this presentation, you acknowledge and agree to the terms set out below.

## Summary information

The material contained in this presentation is intended to be general background information about IMR and its activities current as at the date of this presentation. The information is provided in a summary form and does not purport to be complete or to include all information that an investor should consider when making an investment decision nor does it contain all the information which would be required in a disclosure document or a prospectus prepared in accordance with the requirements of the *Corporations Act 2001* (Cth) (**Corporations Act**). It should be read in conjunction with IMR's periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), which are available at [www.asx.com.au](http://www.asx.com.au).

The information in this presentation has been prepared by IMR in good faith and with due care, but IMR does not make any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information, opinions or conclusions contained in this presentation. Certain information in this presentation has also been sourced from publicly available sources that have not been independently verified.

This presentation is current as at the date of this presentation. The information in this presentation, therefore, remains subject to change. IMR is under no obligation to update the presentation and the information in this presentation remains subject to change by IMR in its absolute discretion and without notice.

None of IMR, its officers, directors, employees and agents, nor any other person makes any representation or warranty, express or implied, as to, or endorsement of, IMR, the accuracy or completeness of any information, statements or representations contained in this presentation and none of them accepts responsibility or liability for any errors or omissions in this presentation whatsoever.

## No financial product advice

This presentation is for information purposes only and does not take into account the investment objectives, financial position or needs of any particular investor. Investors or potential investors should seek independent professional advice in respect of their specific investment objectives, financial situation and particular needs before making any investment decision. IMR is not licensed to provide financial product advice in respect of its securities or any other financial products.

## Risks

An investment in IMR is subject to known and unknown risks, some of which are beyond the control of IMR and its directors. IMR does not guarantee any particular rate of return in relation to IMR securities or the performance of IMR.

Refer to "Risk factors" on page 30 of this presentation for a non-exhaustive summary of certain key business, offer and general risk factors that may affect IMR.

## Forward-looking statements

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management's current expectations and beliefs (being statements about matters that are

not historical facts), including but not limited to, statements related to IMR's financial performance, business strategy and goals, plans and prospects, potential benefits of IMR's products and technology, timing of international regulatory approvals, market size, commercial success, and future financial performance. IMR uses words such as 'will', 'may', 'expect', 'intend', 'seek', 'would', 'should', 'could', 'continue', 'plan', 'estimate', 'anticipate', 'believe', 'probability', 'risk', 'aim', or other similar words to identify forward-looking statements.

Any such statements, opinions and estimates in this presentation speak only as of the date of this presentation, and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of IMR, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Forward-looking statements may also assume the success of IMR's business strategies. The success of any of these strategies is subject to uncertainties and contingencies beyond IMR's control, and no assurance can be given that any of the strategies will be realised in the period for which the forward-looking statements may have been prepared or otherwise.

To the maximum extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining to act as a result of this presentation or its contents is accepted by IMR or any of its officers, employees or agents.

## Past performance

Past performance, including the pro forma historical information in this presentation is given for illustrative purposes only and should not be relied on (and is not) an indication of future performance including future security price information. Historical information in this presentation relating to IMR is information that has been released to the market. For further information, please see past announcements released to the ASX. Nothing contained in this presentation nor any information made available to investors or potential investors is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future.

Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

## No offer

This presentation is for information purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or any other law (and will not be lodged with the Australian Securities and Investments Commission (ASIC)). This presentation should not be considered an offer or an invitation to acquire securities or any other financial products and does not and will not form any part of any contract of any acquisition of any securities in IMR. It should also not be considered an offer or an invitation to acquire securities or any other financial products in any jurisdiction in which, or to any person to whom, it would be unlawful to make such an offer or invitation.

The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction.

# Disclaimer

## Financial information

Investors should note that this presentation may contain unaudited financial information that has been prepared by IMR's management. IMR's results are reported under US GAAP. Certain financial data in this presentation is "non-IFRS financial information" under Regulatory Guide 230 (Disclosing non-IFRS financial information) published by ASIC. All values are stated in Australian dollars unless otherwise stated.

## Notice to U.S. persons: restriction on purchasing CDIs on ASX

IMR is incorporated in the State of Delaware and its securities have not been registered under the U.S. Securities Act of 1933 as amended (US Securities Act) or the laws of any state or jurisdiction in the United States. IMR's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation. As a result, the CDIs are "restricted securities" (as defined in Rule 144 under the US Securities Act) and may not be sold or otherwise transferred except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act. For instance, US persons who are qualified institutional buyers ("QIBs", as defined in Rule 144A under the US Securities Act) may purchase CDIs in reliance on the exemption from registration provided by Rule 144A. To enforce the transfer restrictions, the CDIs bear a FOR Financial Product designation on ASX. This designation restricts CDIs from being purchased by US persons except those that are QIBs. In addition, hedging transactions with regard to the CDIs may only be conducted in compliance with the US Securities Act.

Neither Morgans Corporate Limited (ACN 010 539 607), Canaccord Genuity (Australia) Limited (ACN 075 071 466), nor Taylor Collison Limited (together the **Joint Lead Managers**), nor any of their or IMR's respective advisers nor any of their respective affiliates or related bodies corporate, nor any of their respective directors, officers, partners, employees or agents (together, the **Beneficiaries**), have authorised, permitted or caused the issue, submission, dispatch or provision of this document and, except to the extent referred to in this document, none of them makes or purports to make any statement in this document and there is no statement in this document which is based on any statement by any of them.

To the maximum extent permitted by law, IMR, the Joint Lead Managers and their respective advisers, and each of their respective Beneficiaries exclude and disclaim all responsibility and liability, including, without limitation, for negligence or for any expenses, losses, damages or costs incurred by you as a result of the information in this document being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise.

To the maximum extent permitted by law, IMR, the Joint Lead Managers and their respective advisers, and each of their respective Beneficiaries make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this document and, with regards to the Joint Lead Managers, it and its advisers, and each of their respective Beneficiaries take no responsibility for any part of this document or the Capital Raise.

The Joint Lead Managers and their advisers, and each of their respective Beneficiaries make no recommendations as to whether you or your related parties should participate in the Capital Raise nor do they make any representations or warranties to you concerning the Capital Raise. You represent, warrant and agree that you have not relied on any

statements made by the Joint Lead Managers, their advisers, or any of their respective Beneficiaries in relation to the Capital Raise. You further expressly disclaim that you are in a fiduciary relationship with any of IMR, the Joint Lead Managers or their advisers or any of their respective Beneficiaries.

To the maximum extent permitted by law, you agree to release and indemnify IMR, the Joint Lead Managers and their respective advisers from and against all claims, actions, damages, remedies or other matters, whether in tort, contract or under law or otherwise, arising from or which may arise from or in connection with the provision of, or any purported reliance on, this document and you covenant that no claim or allegations will be made against any of the them in relation to this document.

You acknowledge and agree that determination and eligibility of investors for the purposes of the Capital Raise is determined by reference to several matters, including legal and regulatory requirements and the discretion of IMR and the Lead Manager. You further acknowledge and agree that IMR and the Joint Lead Managers and their respective Beneficiaries exclude and expressly disclaim any duty or liability (including for negligence) in respect of the exercise of that discretion, to the maximum extent permitted by law.

## Acknowledgement and representation and warranty

By receiving this document you acknowledge and agree that you understand the contents of this notice and that you agree to abide by its terms and conditions. By receiving this document you further agree, irrevocably and unconditionally, to submit to the non-exclusive jurisdiction of the courts of Victoria, in respect of any disputes, actions, suits or proceedings arising out of, or relating to, this document.

# Executive Summary



## Imricor background

- Imricor (**IMR** or the **Company**) is the global leader in the design and development of MRI compatible interventional medical devices. The Company has dedicated 20 years to building an entire ecosystem of capital equipment, consumable devices and software to enable physicians to unlock the superior soft tissue imaging of magnetic resonance imaging (**MRI**) during interventional procedures.
- Following scientific validation, including the world's first ischemic Ventricular Tachycardia (VT) ablation performed under real-time MRI guidance in an ICD patient, and supported by strong U.S. regulatory momentum, Imricor is preparing to scale operations to disrupt the growing cardiac ablation market.
- Over 90 patents, deep technology integration and relationships with major MRI vendors, combined with a growing regulatory moat provide a difficult to replicate ecosystem of technology to grow into a major global MedTech Company

## Unique value proposition

- The only provider of commercially viable MRI compatible cardiac ablation system
- Value accretive across all stakeholders by demonstrating superior patient outcomes, increased profitability for hospitals, reduced procedure times for doctors and lower overall costs for payors
- Significant growth opportunity within a large and established addressable market, projected to grow at a ~15% CAGR to ~\$60bn by 2035
- Platform compatibility across major MRI vendors, with expanding opportunities in paediatrics following submission of a 510(k) application for label expansion.

## Equity raising overview

- IMR is launching an approximately \$60.0 million institutional placement (**Placement**) representing approximately 10.1% of existing shares on issue to Australian and Global institutions.
- The offer price under the Placement of \$1.85 per share (**Offer Price**) represents a 6.3% discount to the last traded price on Wednesday, 29 April 2026 and a 7.4% discount to the volume weighted average trading price over the 5-trading-day period ending Wednesday, 29 April 2026.
- Morgans Corporate Limited, Canaccord Genuity Australia Limited and Taylor Collison Limited are acting as Joint Lead Managers to the Placement.

# Executive Summary



## Key outcomes of Equity Raising

- Successful completion of the Offer will provide the Company with a cash runway extending into 2028, enabling the Company to:
  - Establish an installed base of NorthStar customers among U.S. based Pediatric Hospitals during CY2026;
  - Secure the regulatory approvals for the entire Electrophysiology platform in the U.S;
  - Fund the rollout in 2027 and beyond to the more than 50 hospitals with existing CMR facilities as well as new greenfield sites;
  - Complete VISABL-VT clinical trial in Europe and accelerate pipeline conversion;
  - Invest in dedicated resources for Middle East expansion;
  - Complete VT trial and gain FDA approval for VT label in the U.S;
  - Progress development of PFA platform and clinical trial in the U.S. for treating Atrial Fibrillation leveraging the existing technology suite;
  - Expand portfolio of approved products such as biopsy catheter and other interventional tools; and
  - Accelerate NorthStar development to increase functionality and broaden use cases beyond cardiology.

ersonal use only

# Imricor is bringing MRI into X-Ray based cath labs

From inferring



- Radiation exposure
- Lead protection required
- Point by point mapping
- Additional devices and costs
- No soft tissue visible under x-ray
- Inability to assess lesion quality and durability

IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR)

To visualizing



- No radiation
- No lead protection
- Soft tissue visible in exquisite detail
- Maps generated in minutes with NorthStar
- No need for ICE or mapping catheters

**imricor**

WWW.IMRICOR.COM

# Imricor's solution – adding value to all stakeholders



Patient	Doctor	Hospital	Payer
<ul style="list-style-type: none"> <li>• Higher single procedure success rates achieved in clinical trials for AFL patients</li> <li>• Single procedure success is expected to result in lower overall treatment costs per patient</li> <li>• Faster average procedure times in clinical trials for AFL patients</li> <li>• No radiation exposure</li> </ul>	<ul style="list-style-type: none"> <li>• Improved visualisation of heart anatomy and lesion verification</li> <li>• Faster procedures can allow for more cases per day</li> <li>• No radiation exposure</li> <li>• No lead garments to wear and therefore avoid potential occupational injuries</li> </ul>	<ul style="list-style-type: none"> <li>• Similar cost to set up an iCMR EP lab compared to X-ray EP lab</li> <li>• iCMR EP lab can be used for diagnostic imaging when not being used for interventions</li> <li>• Shorter procedure times = higher volume</li> <li>• Radiation eliminated for patients, physicians, and staff</li> <li>• Similar or lower cost per procedure; improved patient treatment</li> </ul>	<ul style="list-style-type: none"> <li>• Similar or lower per-procedure costs</li> <li>• Lower overall cost per patient expected to result from higher single procedure success rate</li> <li>• Existing reimbursement applies</li> </ul>

Personal use only

# Attractive business model - capital sales + high margin recurring revenue



MRI compatible equipment	Vendor	Revenue type
Ablation catheter	Imricor	Consumable
Diagnostic catheter	Imricor	Consumable
Transseptal puncture kit	Imricor	Consumable
Dispersive electrode	Imricor	Consumable
NorthStar 3D Mapping System	Imricor	Purchase + Annual licenses
Ablation generator	Imricor	Capital + annual service
MR Advantage EP Recorder/Stimulator	Imricor	Capital + annual service
MR Wireless Headsets	OptoAcoustics	Capital + annual service
12-lead ECG	MiRTLE Medical	Capital + annual service
In-room Displays	Nordic NeuroLab	Capital + annual service
Defibrillator	MIPM	
Patient Monitor	Philips	
MRI Scanner	Siemens, Philips, GE	

**Imricor captures 100%** of the consumable catheter revenue for each procedure



# iCMR Lab Economics - Hospital

better outcomes, higher throughput, higher margins

US Top 50 Hospitals by volume	AFL	VT	Afib	Total
Average procedures pa	434	173	1010	1617
Imricor estimated ASP US\$ per procedure	\$4000	\$6500	\$6500	
Revenue opportunity per hospital for Imricor	\$1.7m	\$1.1m	\$6.6m	\$9.43m
Device cost savings per hospital pa*	\$192k	\$539k	\$3.89m	\$4.62m

\*Savings do not include lab time savings which can exceed \$2000 per hour

# iCMR Lab Economics : Imricor

Each new lab installation generates  
US\$500k-US\$700k of capital revenue



## ATRIAL FLUTTER

Procedures: 100 +/-  
ASP : US\$4000

Recurring revenue \$400k



## VT

Procedures: 100 +/-  
ASP : US\$6500

Recurring revenue  
\$650k



## AFIB

Procedures: 300 +/-  
ASP : US\$6500

Recurring revenue  
\$1.95m



## Total Potential Revenue per Hospital

Procedures: 500\* +/-

Recurring revenue \$3m  
per hospital

Future products like biopsy  
probe not included

# Delivering key milestones in 2025

## Regulatory & Clinical

- CE Mark approval under MDR for 2<sup>nd</sup> generation ablation catheter and capital equipment
- CE mark approval received for NorthStar – world's only MRI native 3D mapping and guidance system
- Successfully performed first-in-human ischemic VT ablation under real time MRI guidance
- Successfully completed human factors study involving circa 20 U.S. hospitals to support FDA approval
- Added Charité in Berlin to VISABL-VT study
- Submitted NorthStar and Vision-MR Diagnostic Catheter for 510(k) clearance by FDA
- Added UVA Health as 2<sup>nd</sup> U.S. hospital to join VISABL-AFL clinical trial
- World first in vivo PFA ablations performed in the ventricle under real time MRI guidance

## Commercial

- Completed integration and testing of NorthStar on Philips MRI platform unlocking Philips sites
- Completed hiring and training of European sales team
- European customer pipeline grew from 7 in Q4 24 to 40 in Q4 25
- Construction of iCMR labs commenced in Saudi Arabia with completion expected CY26
- ~100 doctors attended the iCMR summit in Saudi Arabia hosted by Imricor and KOL from Amsterdam

## Financial

- FY25 revenue of US\$292k temporarily impacted by customer sites performing clinical trial cases
- Strengthened balance sheet in FY25 to support growth via a cUS\$44m institutional placement
- Costs well managed with operating cash outflow of US\$19m in FY25
- US\$32.9m cash and marketable securities as at Mar 31<sup>st</sup> 2026

# Looking ahead to 2026 & beyond

ersonal use only

## Board of directors strengthened to support growth and commercialisation



“Throughout my 30-year career at companies such as Medtronic and Johnson & Johnson MedTech, I have witnessed remarkable innovations that have reshaped the landscape of healthcare and improved millions of lives. Yet it is rare to encounter a technology with the potential to redefine an entire field as profoundly as Imricor’s MRI-guided platform. What Imricor has developed is not an incremental improvement. It represents a paradigm shift in the way electrophysiology and other interventional procedures are performed.”

**Aldo Denti**

Non-executive Director - Imricor

# A strong and growing market in cardiac ablation

A large global addressable market with high growth potential supported by favourable growth drivers

## Drivers of global catheter ablation market



Increased incidence of cardiac disease



Shift towards minimally invasive procedures




Cost effectiveness of catheter ablation as treatment option

### Sources:


S&S Insider Strategy and Stats

## Electrophysiology Device Market (US\$bn)



# Pipeline benefiting from investment in sales

## European active pipeline is rebuilding



Imricor's products are currently approved in 31 countries, with 8 countries containing customer sites



Estimated over 1,500,000 ablation procedures across the US, EU and Aus in 2026, with growth in these markets estimated at 15% CAGR to 2032



Average estimated consumable revenue of USD \$3,500 - \$6,500 per procedure depending on indication and market




Expected US, ANZ, Nordics, and additional Middle East countries will be activated within the next 6-12 months

# NorthStar – Cleared and ready for commercialisation

# NorthStar

## Mapping System



Key piece of the infrastructure, intended to be the central hub of every iCMR lab



AI powered application potential well beyond cardiac ablation



Strong in-bound interest from hospitals



Solves problem for pediatric hospitals where radiation minimisation is a key priority



Regulatory status



European CE mark received



US FDA cleared



Pediatric label expansion submitted

# Several key value drivers during 2025/26



FDA Approval for US commercial release of platform technology

- 510(k) submissions / approvals
- VISABL-AFL clinical trial expands in U.S.
- PMA submissions / approvals



VISABL-VT clinical trial

- Expansion of trial in EU to high volume sites with strong KOL's



NorthStar Mapping System U.S. Market Launch



New site activations, growing installed base globally



Middle East first procedures and further expansion



Pipeline building in United States following NorthStar approval



Pulsed Field Ablation (PFA) research, publications, and product development

Personal use only

# Equity Raising Summary

ersonal use only



IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR)

[WWW.IMRICOR.COM](http://WWW.IMRICOR.COM)

# Equity Raising Summary

<b>Offer Size and Structure</b>	<ul style="list-style-type: none"><li>▪ Imricor is seeking to raise approximately A\$60.0 million via a single tranche institutional placement (<b>Placement</b>)</li><li>▪ Approximately 32.4 million new fully paid CHESS Depository Interests (<b>New CDIs</b>) to be issued utilising the Company's available placement capacity under ASX Listing Rule 7.1.</li><li>▪ New CDIs issued under the Placement will rank pari passu with existing fully paid CDIs.</li><li>▪ The Placement is not underwritten</li></ul>
<b>Placement Price</b>	<ul style="list-style-type: none"><li>▪ Fixed Placement price of A\$1.85 per New CDI, which as at 30 April 2026, represents a discount of:<ul style="list-style-type: none"><li>▪ 6.3% to the last closing price of A\$1.975 per CDI;</li><li>▪ 7.4% discount to the 5-day volume weighted average price (<b>VWAP</b>) of A\$2.00; and</li><li>▪ 7.7% discount to the 10-day VWAP of A\$2.00.</li></ul></li></ul>
<b>Use of Proceeds</b>	<ul style="list-style-type: none"><li>▪ Placement proceeds will be used to fund sales and marketing, research &amp; development cost, clinical trials, regulatory compliance and general working capital.</li><li>▪ See slide 21 for further details</li></ul>
<b>Syndicate</b>	<ul style="list-style-type: none"><li>▪ Canaccord Genuity (Australia) Limited (<b>Canaccord</b>), Morgans Corporate Limited (<b>Morgans</b>) and Taylor Collison Limited (<b>Taylor Collison</b>) are Joint Lead Managers to the Offer</li></ul>

# Sources and Use of Funds

Sources of Funds	A\$m	%
Placement proceeds	60.0	100.0%
<b>Total sources</b>	<b>60.0</b>	<b>100.0%</b>

Uses of Funds	A\$m	%
Sales and marketing	18.5	31.0%
Research & development	14.4	23.9%
Clinical trials and regulatory compliance	16.2	27.0%
General working capital and costs of the offer	10.9	18.1%
<b>Total uses</b>	<b>60.0</b>	<b>100.0%</b>

Note \*cash and marketable securities balance as at 31/03/2026 of US\$32.9 million converted at foreign exchange rate of A\$0.685/US\$1.00

Post completion of the Placement, IMR will have pro-forma cash balance of **US\$74m / A\$108m\***

- The proceeds will be used launch NorthStar in the U.S. including into Children's hospitals
- Gain FDA clearance for the EP platform in the U.S. in CY2026
- Prepare for full commercial launch targeting sites with existing CMR infrastructure and sites planning expansion/replacement capex
- Complete VISABL-VT trial and launch VT ablations in Europe
- Begin US VT trial early in CY2027 to expand U.S. indications
- Progress development of PFA platform targeting Atrial Fibrillation ablations in the MR
- Invest in dedicated resources for Middle East expansion
- Expand portfolio of approved devices such as biopsy catheter
- Accelerate NorthStar development to increase functionality in and beyond cardiology which will grow recurring license revenue

# Equity Raising Timetable

Event	Date
Trading halt and launch of Placement	30 April 2026
Announcement of completion of Placement and trading halt lifted	4 May 2026
Settlement of New Securities issued under the Placement	7 May 2026
Allotment, quotation and trading of New Securities issued under the Placement	8 May 2026

\*The Placement timetable is indicative only and subject to variation. The Company reserves the right to alter the timetable at its discretion and without notice, subject to ASX Listing Rules and the Corporations Act.

# Questions?

ersonal use only



# Appendix 1 – Additional Information

ersonal use only



# VISABL-AFL Clinical Trial Sites

## DR. AV KOLANDAIVELU

Johns Hopkins University

“MRI is the gold standard for imaging arrhythmia causing heart characteristics, like fibrosis, and for visualizing the effects of ablation. We are enthusiastic to be a part of the FDA approval study for the Imricor ablation system.”



## DR. AJAY PILLAI

Virginia Commonwealth University Health

“Imricor’s Northstar mapping system and Vision-MR mapping and ablation catheters represent a paradigm shift in cardiac ablation. The potential to visualize arrhythmogenic substrate and, crucially, the effects of ablation is extraordinarily impactful and meaningful for patient outcomes.”



## DR. MARCO GÖTTE

Amsterdam University Medical Center

“With MRI-guided treatment of heart conditions, we are working towards fewer procedures per patient, hospital admissions, and less medication. Perhaps MRI-guided treatment of heart disease will become the norm and replace X-ray-driven treatments.”



## PROF. JUERG SCHWITTER

MD, Director Cardiac MR Centre,  
University Hospital Lausanne (CHUV)

“Many years ago in San Francisco, we did pioneering work on coronary artery disease detection by MRI. Now ischemia diagnostics by MRI is in all international guidelines. Similarly, pacemakers and defibrillators were not compatible with MRI 10 years ago. We started a collaboration with industry, and now all leading device manufactures offer a full spectrum of devices, all MRI compatible, reaching market shares up to 100%. **I believe strongly, that this evolution will also happen to the iCMR field, as it allows for high precision interventions,** where we expect higher success rate, lower relapse rate and less complications compared to conventional techniques, and all these advantages go without radiation exposure and potentially shorter interventions times.”



## DR. KENNETH BILCHICK

University of Virginia Health

“Interventional CMR, particularly for electrophysiology applications, promises to advance our therapeutic strategies for patients with atrial and ventricular arrhythmias by facilitating visualization of the catheters used for ablation simultaneously with real-time CMR imaging.”



## DR. EDWARD MARTIN

Oklahoma Heart Institute

“I have been involved with the imaging aspect of cardiac MRI for the last 30 years, and I have seen and participated in many exciting technological advances over that time. I am extremely excited to see the advancements... that allow expansion of cardiac MRI into interventional electrophysiology.”




## DR. LAURENT FIORINA

Cardiovascular Institute of South Paris

“Performing procedures with Imricor’s NorthStar 3D Mapping System is a game changer for this field, and it will have a transformative impact. I look forward to the continued partnership with Imricor.”




# A strong intellectual property portfolio



**Imricor's patents protect technology that allows Imricor to manufacture medical devices that are uniquely MRI compatible.** Trade secrets, 3rd party relationships and difficult regulatory environment leave a deep moat behind Imricor.



In addition to protecting Imricor's devices and procedures, its patents provide an opportunity for the Company to license its technology to 3rd party medical device companies (particularly implant manufacturers) to help make their devices compatible with MRI.



To date, Imricor has executed 3 separate agreements where it has licensed its own patents to 3rd parties for use in implantable devices under which Imricor has received over **US\$12.9m of payments (revenue) to date.**

# Imricor Leadership: Management

**STEVE WEDAN**



*President and Chief Executive Officer, and Board Chair*

**35 years industry experience**

Designed MRI and ultrasound systems for GE Healthcare. United States appointed expert on MR safety and devices. **Credited with establishing the 4<sup>th</sup> known hazard interaction in the MRI**

**GREG ENGLEHARDT**



*Vice President of Global Sales*

**20 years industry experience**

Led global business development initiatives, identifying and capitalizing on new market opportunities to drive international sales growth at NeuroMetrix. **Former combat medic in the U.S. Army**

**NICK TWOHY**



*Vice President of Marketing and Business Development*

**20 years industry experience**

Directed international market strategies for Medtronic's Cardiac Resynchronization Therapies business **Led the successful US launch of the Medtronic Revo MRI pacemaker system, enhancing market.**

**JENNIFER WEISZ**



*Vice President of Regulatory and Quality*

**20 years industry experience**

Contributed to the continuous improvement of the quality and regulatory strategy, development, and implementation during tenure at Medtronic's Global Clinical Operations Quality division. **Experienced in bringing medical devices to market and ensuring their compliance with global standards.**

**VIC FABANO**



*Vice President of Operations*

**25 years industry experience**

Held executive positions in Operations, Quality, and Product Development throughout his tenure including VP of Operations and Quality at Osprey Medical. **Expert in supply chain scaling and operations infrastructure to support rapid growth, profitability, and quality for start-up to midsize medical device firms**

**JONATHON GUT**



*Vice President of Finance and Chief Financial Officer*

**15 years industry experience**

Previous experience at Gail Medical and Boston Scientific driving financial performance, supporting business growth, and ensuring regulatory compliance. **Expertise spans various aspects of financial management, strategic planning, and operational efficiency within the medical device industry.**

**GREGG STENZEL**



*Vice President of Research and Development*

**25 years industry experience**

Led the Instrument Technical Operations division at Beckman Coulter, Inc., a leading manufacturer of In Vitro Diagnostic Systems. **Seasoned executive with expertise in new product development, supply chain management, quality and regulatory systems, and customer support.**

**NICK CORKILL**



*Vice President of Corporate Strategy*

**16 years industry experience**

Experienced capital markets professional having spent 15 years as an equity analyst and portfolio manager at Perpetual Investments, BlackRock Inc and Lennox Capital. **Deep analytical and financial modelling skills across multiple sectors, disciplined approach to capital management.**

**KATE LINDBORG, PHD**



*Vice President of Clinical Affairs*

**13 years industry experience**

Managed a portfolio of clinical trials within Medtronic's Cardiac Rhythm and Heart Failure and Diagnostics Clinical division to gain and maintain market approval of novel devices. **Oversaw the generation and dissemination of clinical evidence, enhancing the scientific credibility and market positioning of Medtronic's products.**

# Imricor Leadership: Board of directors



**STEVE WEDAN**

*President and Chief Executive Officer, and Board Chair*

Designed MRI and ultrasound systems for GE Healthcare. United States appointed expert on MR safety. Mr Wedan is a member of various international standards committees in the fields of MRI safety and the compatibility of implanted and interventional products in MRI

Credited with establishing the 4<sup>th</sup> known hazard interaction in the MRI



**MARK TIBBLES**

*Deputy Chair and Lead Independent Director*

Entrepreneur, business owner, company director and active venture investor in and advisor to technology, life science and medical device companies

Owner and managing member of STEM Fuse, LLC, one of the largest providers of digital K-12 STEM curriculum in the U.S.

Managing Director of Strategic Stage Ventures, LLC.



**PETER MCGREGOR**

*Non-executive Director*

Extensive finance management background including partner positions at Goldman Sachs JBWere, and managing director in the institutional banking & markets division of Commonwealth Bank of Australia

Currently serves as a Director of Treasury Corporation of Victoria and True Infrastructure Management Pty Ltd.



**ANITA MESSAL**

*Non-executive Director*

Comprehensive background in health care and benefits industry, including the successful integration of merged and acquired entities across all areas of the business at AccentCare

Vast background in working with both Fortune 100 and startup companies in public, private and non-profit sectors in both domestic and international markets



**JEFFREY LEIGHTON**

*Non-executive Director*

Dr Leighton is a cognitive neuroscientist with extensive experience in both academic and corporate settings. He holds a PhD in Cognitive Psychology from Grand Canyon University and has a robust research, teaching, and leadership background.

Beyond his academic achievements, Dr Leighton has demonstrated strong business acumen as CFO at NDS Wellness.

Dr Leighton has held key corporate governance and advisory roles.



**ALDO DENTI**

*Non-executive Director*

Mr Denti has over 30 years of global experience in the medical device industry. Mr Denti is currently the Chief Commercial Officer for Dentsply Sirona. Prior to this role, he was the Company Group Chairman of Global Orthopaedics for Johnson & Johnson MedTech. Since becoming Company Group Chairman in 2019, Mr Denti grew the business to US\$9 billion in annual sales, making it the world's largest orthopaedics company. Mr Denti was responsible for leading a staff of over 25,000 employees.

Prior to his role in orthopaedics, Mr Denti served as Global Leader at Johnson & Johnson Vision, where he modernized the organization and introduced critical new skill sets in strategic planning, insights & analytics, e-commerce, and business model innovation. Mr Denti holds a Bachelor of Arts, with Specialised Honors, from York University

# Key terms

<b>Vision-MR Ablation Catheter</b>	<ul style="list-style-type: none"><li>• Medical device developed by Imricor, designed for use within an MRI</li><li>• World first, no competitors, all others only compatible with X-ray</li></ul>
<b>Cardiac Arrhythmias</b>	<ul style="list-style-type: none"><li>• Irregular heartbeat, affects approximately 2% of US population</li><li>• Expected to double to 4% of US population by 2030</li><li>• Ventricular arrhythmias are responsible for 75% - 85% of sudden cardiac deaths, and are a leading cause of strokes</li></ul>
<b>Ablation</b>	<ul style="list-style-type: none"><li>• Minimally invasive surgical procedure to restore heart to normal heartbeat</li></ul>
<b>Catheter Ablation</b>	<ul style="list-style-type: none"><li>• Physician will guide catheter into heart</li><li>• Physician will then apply energy (radiofrequency, cryo, pulsed field) with the purpose of forming scars/lesions that destroy the heart cells responsible for causing the electrical misfiring</li></ul>
<b>X-ray vs MRI</b>	<ul style="list-style-type: none"><li>• X-rays are good for bones and bone density, not as effective at visualizing soft tissues like muscles, ligaments, and organs</li><li>• MRI provides excellent contrast between different types of soft tissues, making it ideal for imaging the heart</li><li>• CMR is the field of MRI used by cardiologists (“Cardiac MR”)</li><li>• CMR field has grown over 500% since 1998</li></ul>
<b>iCMR Lab: Interventional Cardiac Magnetic Resonance</b>	<ul style="list-style-type: none"><li>• A speciality interventional lab fitted with MRI used by cardiologists (interventional + CMR = iCMR)</li><li>• Earning potential of over US\$1 million p.a. more than a standard X-ray lab for each hospital performing 500 procedures per year</li></ul>

# Appendix 2 – Risk Factors

ersonal use only



# Risk Factors

Please see Imricor's ASX Announcement "Form 10 Registration with the U.S. Securities and Exchange Commission" dated 19 March 2026, and the Amendment to Form 10 dated 28 April 2026 for a complete list of Risk Factors included in the Form 10.

**Regulatory:** Imricor will, subject to regulatory clearances, seek to sell its key products in the European Union, the U.S., the Middle East and other jurisdictions. Imricor is not assured of receiving future regulatory clearances and approvals for other indications or in other jurisdictions, and cannot predict with certainty the timelines for such clearances and approvals, or other requirements that may be imposed by regulatory authorities (e.g. further clinical trials or other requirements to prove the safety and effectiveness of its products). In addition, future changes or updates to Imricor's products which affect their safety or efficacy may require new regulatory clearance or approval in some jurisdictions before Imricor may sell the revised product. Any barriers or delays to Imricor obtaining future regulatory clearances would limit the size of the market opportunity for Imricor's ablation system.

**Market Adoption:** Imricor's business model depends on hospitals and clinics with ablation centres in markets where it obtains the required regulatory approvals establishing an iCMR lab and adopting Imricor's MRI-compatible technology for cardiac catheter ablation procedures. The time to establish an iCMR lab can also vary significantly from months to years depending on the individual hospital and clinic and its internal processes. If MRI-guided technology for cardiac catheter ablation procedures is not increasingly adopted or favoured by hospitals and clinics, along with physicians, Imricor's ability to achieve its growth strategy and generate revenue will be significantly impaired.

**Competition:** Imricor expects to generate the vast majority of its future revenue from the sale of its products used for MRI-guided cardiac catheter ablation procedures. The medical device industry is competitive, subject to rapid change and significantly affected by new product introductions. Although Imricor believes that there are currently no products or technologies that are commercially comparable to Imricor's MRI-compatible cardiac catheter ablation products, there are a number of other products and devices on the market which are not traditionally MRI-compatible but which are commonly used to perform conventional cardiac catheter ablation procedures. To this end, Imricor compete with larger companies who manufacture and sell ablation and diagnostic electrophysiology products, including Abbott Laboratories, Boston Scientific Corp., Johnson & Johnson Inc., and Medtronic, Inc. If competitors develop new products (which could include devices or drugs) or technologies that offer better combinations of price and performance than Imricor can offer for the treatment of arrhythmia, Imricor's products or future products may become obsolete or not competitive, which would have a significant negative effect on Imricor's business and financial position.

**Commercialisation:** Historically, Imricor generated revenue from licensing some of its intellectual property for use in implantable devices and performing contract research but expects to generate most of its future revenue from the sale of the MRI-compatible products it has developed for use in cardiac catheter ablation procedures (comprising single-use consumables and capital goods). Imricor is currently in the early stages of commercialising its key MRI-compatible products in the European Union, the Kingdom of Saudi Arabia, and Qatar. Imricor has incurred net losses since inception, have never been profitable, and there is no assurance that Imricor will achieve or sustain profitability or positive cash flow in the future. Imricor faces the risks typically encountered by companies early in their commercialisation, particularly those developing and selling medical devices.

**Limited Sales and Marketing Resources:** Imricor currently has limited sales and marketing resources and will need to, among other things, expand its sales team. Imricor will sell all of its products to hospitals and clinics either directly or through distributors and will therefore need to commit increased resources to product sales and marketing to execute its current growth strategy. There is a risk that Imricor will be unable to develop sufficient sales and marketing capabilities to effectively commercialise its products and maintain a competitive position in its market

**Capital Reserves may not be Adequate:** Even with proceeds of the Offer, Imricor's capital reserves may not be adequate to fund its operations and execution of its strategic objectives. Imricor intends to use its funds primarily to support the commercial launch of its products in the European Union, the Middle East, and the United States, as well as to advance its ongoing and planned clinical development programs in the United States, European Union, and other jurisdictions. Imricor may decide to use the proceeds differently from its current plans or may need to obtain additional funding to continue operations (or both). If Imricor raises additional funds by issuing equity securities, the interests held in Imricor by shareholders and CDI Holders may be diluted. Debt financing, if available, may involve covenants restricting Imricor's operations or its ability to incur additional debt. Imricor cannot guarantee the future availability of funds or that the funds will be available on terms that are favourable to it. If Imricor requires additional funding and is unable to raise these funds, it could adversely impact Imricor's business.

**Manage Growth:** As Imricor only has limited experience in manufacturing its products in commercial quantities, it may encounter delays or shortfalls which may be caused by many factors. If Imricor is unable to keep up with demand for its products, its growth could be impaired, market acceptance for its products harmed and physicians may elect to use competitor's products. Imricor's inability to successfully manufacture its products in sufficient quantities would materially harm its business. Imricor expects that its current manufacturing capabilities will be sufficient to support its projected growth profile through the end of 2027. If Imricor gains significant market share over and above its current short-term expectations and, in any case, from mid-2028 onwards, it will need to expand its manufacturing capacity, including additional facilities, and invest in systems and processes to support the development of the business. The failure of Imricor to address projected growth in a timely, robust and efficient manner may negatively impact Imricor's financial performance.

**Supplier Risk:** Imricor's products include components that are manufactured and supplied by third parties. There are inherent risks in relying on third party suppliers for Imricor's product components, especially since any change to the manufacturing process of an approved medical device requires significant documentation and, in many cases, supplemental testing. Certain components and products that meet Imricor requirements are available only from a single supplier or a limited number of suppliers. A disruption at a key supplier could cause a substantial delay in the availability of Imricor's products, leading to a potential loss of sales.

**Single Manufacturing Location:** Imricor performs all of its manufacturing activities at its headquarters in Burnsville, Minnesota. Should operations at the facility be disrupted or production halted for any reason (e.g. due to labour strikes, extreme weather, issues arising from FDA or other regulatory inspections or other events outside Imricor's control), Imricor may incur significant costs and disruptions that could reduce its revenues and harm its business, reputation, and financial results. While alternative arrangements could be made to transfer the manufacturing process to a different facility, this would take some time and may involve other risks. The regulatory process for approval of facilities is time-consuming, and Imricor's ability to rebuild facilities would take a considerable amount of time and expense and cause a significant disruption in service to its customers. If such disruption were to occur, it would adversely affect Imricor's ability to sell its products and customers might instead purchase ablation products from Imricor's competitors. There may also be an ongoing sales impact in the form of a reduction of goodwill as a result of Imricor being unable to supply hospitals, clinics and physicians with the product in a timely manner.



# Risk Factors

**Intellectual Property Rights:** The protection of the intellectual property relied upon by Imricor is critical to its business and commercial success. If Imricor is unable to protect or enforce the intellectual property rights embodied in its products, there is a risk that other companies will incorporate the intellectual property into their technology, which could adversely affect Imricor's ability to compete in the cardiac catheter ablation market. Imricor's patent portfolio comprises of 21 issued U.S. patents, 71 corresponding granted foreign patents and 10 pending applications in national phase or published applications. No assurance can be given that new pending applications will result in granted patents. Furthermore, there is a risk that Imricor's granted patents could be found by a court to be invalid or unenforceable or revoked before their planned expiry. There is also the risk that the granted patents may not provide Imricor with sufficient protection against competitive products and therefore Imricor may not be able to prevent competitors from copying its products and technology. If Imricor's patents and other intellectual property rights do not adequately protect its products, Imricor may lose market share to its competitors and be unable to operate its business profitably.

**Intellectual Property Disputes:** Imricor does not believe that its activities infringe any third party's intellectual property rights. However, in the future Imricor may be subjected to infringement claims or litigation arising out of patents and pending applications of its competitors, or third parties or intellectual property authorities may re-examine the patentability of licensed or owned patents. The defence and prosecution of intellectual property claims are costly and time consuming to pursue, and their outcome is uncertain. If Imricor infringes the rights of third parties, Imricor could be prevented from selling products, which would have a significant negative effect on Imricor's business and financial position.

**Quality Standards:** The manufacturing facilities for Imricor's products must meet stringent quality standards including compliance with the FDA's Quality System Regulations in the United States and equivalent quality management standards internationally. Compliance with these complex quality system requirements is costly and resource-intensive. To maintain CE mark approval, Imricor's Notified Body will regularly audit Imricor and its suppliers. Although Imricor has passed all audits to date, any failure to comply with the applicable regulatory requirements in the future can result in, among other things, temporary manufacturing shutdowns, product recalls, product shortages, bans on imports and exports and a damaged brand name.

**Retain Skilled Staff:** Imricor's long term growth and performance is dependent on attracting and retaining highly skilled staff. Despite having structured incentive programs, there is a risk that Imricor will be unable to attract and retain the necessary staff to pursue its business model. Competition for skilled personnel in Imricor's market is intense. In particular, if Mr. Steve Wedan, Imricor's CEO and a founder, was to leave Imricor, it would lose significant technical and business expertise and Imricor may not be able to find a suitable replacement. This would affect how efficiently Imricor operates its business and its future financial performance could be impacted.

**Reimbursement for Imricor's products:** Imricor expects its products will generally be purchased by hospitals and clinics who will then seek reimbursement from various public and private third-party payers once those products are used to provide health care services to patients. Existing reimbursement codes apply to the sale of the Vision-MR Ablation Catheter and Vision-MR Diagnostic Catheter in the European Union and Imricor also expects its products will qualify for reimbursement codes in the U.S. There is no assurance however, that third-party payers will provide adequate reimbursement for hospitals and physicians to consider Imricor's products cost-effective for patients requiring ablation procedures. In addition, the overall amount of reimbursement available for ablation procedures could decrease in the future. If third-party payer reimbursement to providers for procedures involving Imricor products are eliminated or reduced, some of Imricor's target customers may be unwilling to purchase Imricor products and may choose to instead purchase less expensive alternatives from Imricor's competitors.

**Compliance with laws:** Imricor is only permitted to market, promote, label or train physicians in its ablation products for the uses cleared by the relevant regulatory bodies in each market. If Imricor is deemed to have in any way promoted its products for off-label use, Imricor could be subject to injunctions, fines or other penalties by regulatory bodies. This could cause damage to Imricor's reputation and market adoption of its products may be impaired.

**Tariff risk and other trade actions:** The U.S. government has imposed, and may continue to impose, tariffs and other trade restrictions on imports from various countries, including tariffs on medical devices, components, raw materials, and related goods. Imricor faces material exposure to the effects of U.S. trade policy and retaliatory tariffs imposed by foreign governments, particularly in its key international markets. The tariff environment remains highly fluid, with frequent policy changes, legal challenges to tariff authority, and ongoing trade negotiations. If trade tensions escalate further or retaliatory tariffs are imposed on U.S. medical device exports, Imricor's ability to penetrate and expand in international markets could be materially adversely affected, international revenue growth could be substantially delayed or reduced, and the ability to achieve profitability and positive cash flow could be materially impaired.

**Exchange rate risk:** Although Imricor intends to seek regulatory approval to place its key MRI-compatible products on the market in the U.S., unless and until Imricor obtains such regulatory approvals, it expects to derive a significant portion of its revenue in the foreseeable future from the sale of its key MRI-compatible products in the European Union and the Middle East. Revenue from products sold in the European Union will largely be denominated in Euros, while Imricor's functional and reporting currency is the U.S. dollar. Imricor's results of operations and cash flows will be subject to fluctuations due to changes in foreign currency exchange rates, which could harm its business in the future. Further, the proceeds of the Offer will be received in Australian dollars, while Imricor's functional currency is U.S. dollars. Imricor is not currently hedging against exchange rate fluctuations, and consequently it will be at the risk of any adverse movement in the U.S. dollar-Australian dollar exchange rate.

**Customer budget constraints:** Imricor's ability to generate revenue will largely depend on how effectively it can market and sell its MRI-compatible cardiac catheter ablation products to the healthcare industry. Hospitals and healthcare organisations are constantly facing significant budget constraints, the competition for limited capital budgets is intense and the budget allocation process and approvals for spending on medical devices is complex and time consuming, unpredictable and results highly variable. These factors may cause Imricor's operating results to fluctuate or adversely affect Imricor's ability to achieve its forecasted growth strategy.

**Product liability claims:** The medical device industry is subject to substantial litigation, and Imricor will face an inherent risk of exposure to product liability claims in the event that the use of Imricor's products results or is alleged to have resulted in adverse effects to a patient. Imricor may incur material liabilities relating to product liability claims, although Imricor maintains product liability insurance, Imricor cannot assure you that the coverage limits of its insurance policies will be adequate, or that insurance will be available to it on acceptable terms, if at all. A product liability or other claim with respect to uninsured liabilities or in excess of its insurance coverage would materially impact its business, financial condition, and operating results.

**Ability to achieve a return on an investment in Imricor will largely depend on an appreciation in the market price of the CDIs:** The New CDIs to be issued pursuant to the Offer carry no guarantee with respect to the payment of dividends, return of capital or market value. As Imricor does not currently intend to pay dividends on its Shares in the foreseeable future, investors' ability to achieve a return on their investment in Imricor will depend on an appreciation in the market price of the CDIs. There is no guarantee that the CDIs will appreciate in value or even maintain the same level as the offer price. Accordingly, there is a risk that investors may not achieve any return on their investment

# Risk Factors

**The costs and management time involved in complying with Delaware laws, Australian laws and U.S. reporting requirements are likely to be significant:** Imricor has lodged a Form 10 and an Amendment to Form 10 with the Securities and Exchange Commission (SEC) and will shortly become a U.S. reporting company. As a U.S. reporting company, Imricor will need to file annual, quarterly, and current reports on Forms 10-K, 10-Q and 8-K. In the absence of a waiver from the Listing Rules, these SEC periodic reports will be in addition to Imricor's periodic filings required by the Listing Rules. At the time Imricor becomes subject to the reporting requirements of the U.S. Exchange Act, Imricor will also become subject to the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, which will impose additional governance and reporting obligations. The legal and accounting costs and management time that will be required to comply with these obligations are expected to be significant. As a Delaware company with an ASX listing and a registration as a foreign company in Australia, Imricor will also need to ensure ongoing compliance with Delaware law and relevant Australian laws and regulations, including the ASX Listing Rules and certain provisions of the Corporations Act. To the extent of any inconsistency between Delaware law and Australian law and regulations, Imricor may need to make changes to its business operations, structure, or policies to resolve such inconsistency. If Imricor is required to make such changes, this is likely to result in interruptions to its operations, additional demands on key managers and extra costs.

**Mergers and acquisitions:** Certain provisions of Imricor's Certificate of Incorporation and Bylaws could discourage, delay or prevent a merger, acquisition, tender offer or other means of effecting a change of control of Imricor that Shareholders and CDI Holders may consider favourable, including transactions in which CDI Holders might otherwise receive a premium for their CDIs. Furthermore, these provisions could frustrate attempts by Shareholders and CDI Holders to replace or remove members of the Board or make other changes in management. These provisions could also limit the price that investors might be willing to pay in the future for the CDIs, thereby depressing the market price of the CDIs. There is also a risk that Shareholders and CDI Holders who wish to participate in these transactions or other actions may not have the opportunity to do so. In addition, Imricor is governed by the provisions of section 203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit certain interested Shareholders, in particular those owning 15% or more of the voting rights on Shares, from merging or engaging in various other business combinations with Imricor for a prescribed period.

**Exclusive forum:** Imricor's Bylaws provide that unless Imricor consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain actions involving Imricor. Any person or entity purchasing or otherwise acquiring any interest in shares of Imricor's capital stock (including holders of New CDIs) will be deemed to have notice of, and consented to, this forum selection provision. This provision in Imricor's Bylaws may have the effect of discouraging lawsuits against Imricor or its Directors and officers and may limit the ability of Shareholders and CDI Holders to obtain a favourable judicial forum for disputes with Imricor.

The exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act, the Securities Act, or any other claim for which the federal courts have exclusive jurisdiction. The exclusive forum provision will result in increased costs for investors to file lawsuits against us

# Appendix 4 – International Selling Restrictions

ersonal use only



# International Selling Restrictions

This document does not constitute an offer of CDIs in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the CDIs may not be offered or sold, in any country outside Australia except to the extent permitted below.

## International Offer Restrictions

This document does not constitute an offer of new shares of common stock as represented by CHES Depositary Interests (“CDIs”) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the CDIs may not be offered or sold, in any country outside Australia except to the extent permitted below.

### Germany

This document has not been, and will not be, registered with or approved by any securities regulator in Germany or elsewhere in the European Union. Accordingly, this document may not be made available, nor may the CDIs be offered for sale, in Germany except in circumstances that do not require a prospectus under Article 1(4) of Regulation (EU) 2017/1129 of the European Parliament and the Council of the European Union (the “Prospectus Regulation”).

In accordance with Article 1(4)(a) of the Prospectus Regulation, an offer of CDIs in Germany is limited to persons who are “qualified investors” (as defined in Article 2(e) of the Prospectus Regulation).

### Hong Kong

WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the “SFO”). Accordingly, this document may not be distributed, and the CDIs may not be offered or sold, in Hong Kong other than to “professional investors” (as defined in the SFO and any rules made under that ordinance).

No advertisement, invitation or document relating to the CDIs has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to CDIs that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted CDIs may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities.

The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this document, you should obtain independent professional advice.

### New Zealand

This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (New Zealand) (the “FMC Act”).

The CDIs are not being offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) other than to a person who:

- is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
- meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
- is large within the meaning of clause 39 of Schedule 1 of the FMC Act;
- is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or
- is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.

# International Selling Restrictions

## Singapore

This document and any other materials relating to the CDIs have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of CDIs, may not be issued, circulated or distributed, nor may the CDIs be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the “SFA”) or another exemption under the SFA.

This document has been given to you on the basis that you are an “institutional investor” or an “accredited investor” (as such terms are defined in the SFA). If you are not such an investor, please return this document immediately. You may not forward or circulate this document to any other person in Singapore.

Any offer is not made to you with a view to the CDIs being subsequently offered for sale to any other party in Singapore. On-sale restrictions in Singapore may be applicable to investors who acquire CDIs. As such, investors are advised to acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly.

## United Kingdom

This document has not been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus (within the meaning of Regulation 21 of the Public Offers and Admissions to Trading Regulations 2024 (“POATRs”)) has been published or is required to be published in respect of the CDIs.

This document is issued on a confidential basis to “qualified investors” (within the meaning of paragraph 2 of Schedule 1 to the POATRs) in the United Kingdom. The CDIs may not be offered or sold in the United Kingdom by means of this document or any other document except pursuant to an exemption from the general prohibition on offers of relevant securities to the public in the United Kingdom. This document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom.

Any invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended (“FSMA”)) received in connection with the offer or sale of the CDIs has been, and only will be, communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of the FSMA does not apply to the Company.

In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (“FPO”), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (“relevant persons”). The investment to which this document relates is available only to relevant persons. Any person who is not a relevant person should not act or rely on this document.

# Contact information

## Investors & Australian Media:

**Simon Hinsley**

NWR Communications

[simon@nwrcommunications.com.au](mailto:simon@nwrcommunications.com.au)

+61 401 809 653

## Investors:

**Steve Wedan**

Executive Chair, President & CEO

Email: [steve.wedan@imricor.com](mailto:steve.wedan@imricor.com)

**Nick Corkill**

Vice President, Corporate Strategy

Email: [nick.corkill@imricor.com](mailto:nick.corkill@imricor.com)

## Rest of World Media:

**Nick Twohy**

Vice President, Marketing & Business Development

Email: [nick.twohy@imricor.com](mailto:nick.twohy@imricor.com)

IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR)

FOLLOW US   

**imricor** 

[WWW.IMRICOR.COM](http://WWW.IMRICOR.COM)